Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism

Clinical and Experimental Nephrology

Volumn 16, Issue 2, 2012, Pages 292-299

  Yamamoto, Masahiro ^a   Ogata, Hiroaki ^a   Mizobuchi, Masahide ^b   Yoshida, Noriyo ^a   Kumata Maeta, Chiaki ^b   Koiwa, Fumihiko ^b   Shishido, Kanji ^c   Kinugasa, Eriko ^a  

^a SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c Sekishin kai Kawasaki Clinic   (Japan)

Author keywords

Calcimimetics; Parathyroid hyperplasia; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; STEROL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D STEROL DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE TITRATION; ECHOGRAPHY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PREDICTION; PROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CALCIUM; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID DISEASES; PARATHYROID GLANDS; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863715590     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0547-5     Document Type: Article

References (32)

1. Akizawa T, Kamimura M, Mizobuchi M, Shiizaki K, Sumikado S, Sakaguchi T, Negi S, Ogata H, Kinugasa E. Management of secondary hyperparathyroidism of dialysis patients. Nephrology (Carlton). 2003;8(Suppl):S53-7.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-18.
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca 9 PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-8.
4. Ogata H, Koiwa F, Kinugasa E, Akizawa T. CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol. 2007;11: 261-8.
5. Fukagawa M, Nakanishi S, Fujii H, Hamada Y, Abe T. Regulation of parathyroid function in chronic kidney disease (CKD). Clin Exp Nephrol. 2006;10:175-9.
6. Goto N, Tominaga Y, Matsuoka S, Sato T, Katayama A, Haba T, Uchida K. Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy. Clin Exp Nephrol. 2005;9:138-41.
7. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008; 12:514-525.
8. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42:S1-S201.
9. Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial. 2008;12:49-54.
10. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350:1516-25.
11. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793-800.
12. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transpl. 2008;23:328-35.
13. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248-54.
14. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of endstage renal disease. J Am Soc Nephrol. 2003;14:575-83.
15. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973;4:643-6.
16. Kimata N, Miwa N, Otsubo S, Iwasaki T, Yabuki Y, Miyabe K, Asamiya Y, Sato K, Sugi O, Ikebe N, Kiuchi K, Mineshima M, Akiba T. Achievement of the Japanese Society for Dialysis Therapy guideline targets for mineral metabolism measures: one Japanese university center result. Ther Apher Dial. 2007;11(Suppl 1): S62-6.
17. Komaba H, Igaki N, Takashima M, Goto S, Yokota K, Komada H, Takemoto T, Kohno M, Kadoguchi H, Hirosue Y, Goto T. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: A single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines. Ther Apher Dial. 2008;12:42-8.
18. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760-71.
19. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009; 94:4860-7.
20. Unbehaun R, Lauerwald W. Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis. Clin Nephrol. 2007;67:188-92.
21. Komaba H, Fukagawa M. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: A post-hoc analysis of the KRN1493 study. Ther Apher Dial. 2008;12(Suppl 1):S44-9.
22. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-Term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994;68:221-8.
23. Katoh N, Nakayama M, Shigematsu T, Yamamoto H, Sano K, Saito I, Nakano H, Kasai K, Kubo H, Sakai S, Kawaguchi Y, Hosoya T. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis. 2000;35:465-8.
24. Douthat WG, Orozco SE, de Arteaga J, Massari PU. Treatment of refractory secondary hyperparathyroidism with ethanol injection: the importance of glandular volume. Kidney Int Suppl. 2003;85: S101-S4.
25. Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T, Inaba M, Nishizawa Y. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transpl. 2003;18:2613-21.
26. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:78-86.
27. Tominaga Y, Inaguma D, Matsuoka S, Tahara H, Kukita K, Kurihara S, Onoda N, Tsuruta Y, Tsutsui S, Ohta K, Kuwahara M, Tanaka M, Nishizawa Y. Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial. 2006;10:198-204.
28. Fukagawa M, Kitaoka M, Inazawa T, Kurokawa K. Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens. 1997;6:349-55.
29. Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, Maeda S, Kitazawa R. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58:1980-6.
30. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328-36.
31. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436-43.
32. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004;15:2579-87.